City of Hope | Strategic Alliance Partners

May 24, 2023

Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.

May 23, 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

May 22, 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

May 22, 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

May 19, 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

May 19, 2023

The potential effectiveness of employing placebo in cancer clinical investigation is not difficult to appreciate, but the use of this approach has been, and continues to be, controversial.

May 08, 2023

The addition of venetoclax to lenalidomide and rituximab produced early evidence of clinical efficacy with a tolerable safety profile in previously untreated patients with mantle cell lymphoma.

May 08, 2023

When patients with cancer are asked to be participants in a clinical trial, they are informed that a primary purpose of the investigative effort is to develop objectively valid, generalizable information that may be of value to patients with the same malignancy or benefit researchers in the development of future studies.

April 27, 2023

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

April 27, 2023

Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.

April 27, 2023

In this seventh episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss ongoing research such as the PASS-01 trial (NCT04469556) in pancreatic cancer and ways to translate advances in the metastatic setting to the curative setting.

April 27, 2023

Brian Ball, MD, discusses the significance of targeting RARA in AML, the rationale for SELECT-AML-1, and additional AML research that may contribute to the broadening treatment paradigm in the future.

April 24, 2023

Joshua G. Cohen, MD, FACOG, FACS, expands on the role of PARP inhibitors in the recurrent and up-front settings in ovarian cancer, and the clinical significance of the RUBY and NY-GY018 trials in endometrial cancer.

April 21, 2023

In this fifth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, provide insight into some of the regulatory challenges of organoid development and share expectations for the future of pharmacotyping in treatment selection.

April 20, 2023

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

April 20, 2023

In this fifth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, review the potential advantages of using endoscopic ultrasound to enhance current molecular diagnostic techniques in pancreatic cancer.

April 19, 2023

Brian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.

April 18, 2023

Hemostatic radiation is a method of managing bleeding in patients with gastrointestinal cancers or GI metastases from other primary tumors; however, a multidisciplinary team is required to implement this method, according to Marnee M. Spierer, MD, MBA.

April 14, 2023

In this fourth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, shed light on the process of obtaining sufficient tissue through endoscopic ultrasound–guided biopsies to generate organoids.

April 13, 2023

In this third episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, highlight the three ways in which an organoid can be used to aid clinical sequencing and treatment selection in pancreatic cancer.